Ligand Pharmaceuticals, Inc. (LGND) Misses Q3 EPS by 21c
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q3 EPS of ($0.20), $0.21 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $5.7 million versus the consensus estimate of $5.9 million.